William Blair Has Pessimistic Outlook of PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Stock analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a research note issued to investors on Tuesday, February 25th. William Blair analyst B. Vazquez now anticipates that the company will earn ($0.48) per share for the quarter, down from their prior estimate of ($0.38). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.94) EPS.

PRCT has been the topic of a number of other research reports. Truist Financial reiterated a “buy” rating and issued a $90.00 price objective (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday. Wells Fargo & Company restated an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 price target on the stock. Finally, Morgan Stanley dropped their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $94.29.

PROCEPT BioRobotics Trading Down 1.0 %

PRCT opened at $64.34 on Friday. PROCEPT BioRobotics has a one year low of $45.56 and a one year high of $103.81. The company has a market cap of $3.36 billion, a P/E ratio of -32.99 and a beta of 1.03. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The business’s 50-day simple moving average is $74.93 and its 200-day simple moving average is $79.84.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in shares of PROCEPT BioRobotics by 11.9% in the 4th quarter. FMR LLC now owns 8,159,208 shares of the company’s stock valued at $656,979,000 after buying an additional 866,328 shares during the period. Vanguard Group Inc. lifted its holdings in shares of PROCEPT BioRobotics by 6.1% in the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company’s stock valued at $413,907,000 after buying an additional 297,075 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of PROCEPT BioRobotics by 14.2% in the 4th quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company’s stock valued at $141,110,000 after buying an additional 218,148 shares during the period. Wellington Management Group LLP lifted its holdings in shares of PROCEPT BioRobotics by 38.8% in the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company’s stock valued at $120,051,000 after buying an additional 416,819 shares during the period. Finally, State Street Corp lifted its holdings in shares of PROCEPT BioRobotics by 5.9% in the 3rd quarter. State Street Corp now owns 1,179,514 shares of the company’s stock valued at $94,503,000 after buying an additional 66,175 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the transaction, the chief executive officer now directly owns 152,762 shares in the company, valued at approximately $14,851,521.64. This trade represents a 14.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Alaleh Nouri sold 28,092 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the transaction, the executive vice president now owns 52,472 shares in the company, valued at $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).